PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Aflibercept - Myopic choroidal neovascularisation

PAD Profile : Aflibercept - Myopic choroidal neovascularisation

Keywords :
myopia, CNV
Brand Names Include :
Eylea

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network recommends aflibercept (Eylea) as a treatment option for choroidal neovascularisation in line with NICE TA486 Aflibercept is a payment by results excluded drug and will be considered RED on the traffic light system

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More